Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
Authors' conclusion
HRQoL improved with tirzepatide and semaglutide, with greater improvement in GH with tirzepatide, especially in participants with limited baseline physical function. Participants who lost the most BW showed the greatest improvements in PF, BP, and GH.
Study context
- Population
- Adults with obesity without T2D who received ≥1 dose of study drug (SURMOUNT-5)
- Comparison
- Tirzepatide vs semaglutide
- Primary endpoint
- Change in SF-36v2 norm-based PCS, MCS and domain scores, Patient Health Questionnaire-9 and Patient Global Impression of Status for Physical Activity scores
- Follow-up
- Week 72
Methodological detailson-treatment analysis, prespecified health-related quality of life (HRQoL) outcomes, post hoc subgroup analyses
- On-treatment analysis
- Prespecified HRQoL outcomes
- Post hoc subgroup analyses
Primary result
As reported in the abstract
SF-36v2 scores
- Physical Component Summary (PCS) improved from baseline with both treatments
- p < 0.001
- Mental Component Summary (MCS) did not improve significantly from baseline
- p > 0.05 for both treatment arms
- All domain scores improved
- p ≤ 0.008
Further findings
SF-36v2 in participants with limited baseline physical function (post hoc) · Week 72
- Greater improvement in PCS, Physical Functioning (PF) and General Health (GH) with tirzepatide vs semaglutide
- P ≤ 0.025
- Post hoc
SF-36v2 by body weight (BW) reduction thresholds (pooled, post hoc) · Week 72
- Higher BW reductions associated with more improvement in PCS, PF, Role-Physical, Bodily Pain, GH and Vitality
- Post hoc
- Pooled
Original publication
Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial. Diabetes Obes Metab. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →